This company listing is no longer active
VPA1 Stock Overview
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VPA1 from our risk checks.
AVEO Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.77 |
| 52 Week High | US$15.17 |
| 52 Week Low | US$2.80 |
| Beta | 0.98 |
| 1 Month Change | -1.36% |
| 3 Month Change | -7.83% |
| 1 Year Change | 358.69% |
| 3 Year Change | 155.00% |
| 5 Year Change | -43.57% |
| Change since IPO | -78.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| VPA1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.7% | 1.8% | -1.2% |
| 1Y | 358.7% | -19.8% | 1.8% |
Return vs Industry: VPA1 exceeded the German Biotechs industry which returned 10.7% over the past year.
Return vs Market: VPA1 exceeded the German Market which returned -12.9% over the past year.
Price Volatility
| VPA1 volatility | |
|---|---|
| VPA1 Average Weekly Movement | 1.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VPA1's share price has been volatile over the past 3 months.
Volatility Over Time: VPA1's weekly volatility has decreased from 11% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Michael Bailey | www.aveooncology.com |
AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma.
AVEO Pharmaceuticals, Inc. Fundamentals Summary
| VPA1 fundamental statistics | |
|---|---|
| Market cap | €480.25m |
| Earnings (TTM) | -€26.74m |
| Revenue (TTM) | €86.87m |
5.5x
P/S Ratio-18.0x
P/E RatioIs VPA1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VPA1 income statement (TTM) | |
|---|---|
| Revenue | US$94.32m |
| Cost of Revenue | US$37.79m |
| Gross Profit | US$56.53m |
| Other Expenses | US$85.56m |
| Earnings | -US$29.04m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 59.93% |
| Net Profit Margin | -30.79% |
| Debt/Equity Ratio | 134.1% |
How did VPA1 perform over the long term?
See historical performance and comparison